// App-Quantinova.ai

: Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Researchers

Presenter

  • Pier Luigi Zinzani

Principal Investigators

  • Robert W. Chen

  • Hun Ju Lee

  • Philippe Armand

  • Nathalie A Johnson

  • Pauline Brice

  • John Radford

  • Vincent Ribrag

  • Daniel Molin

  • Theodoros P. Vassilakopoulos

  • Akihiro Tomita

  • Bastian Von Tresckow

  • Margaret A. Shipp

  • Eunhee Kim

  • Akash Nahar

  • Arun Balakumaran

  • Craig H. Moskowitz

Medical Centers

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • City of Hope National Medical Center, Duarte, CA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Dana-Farber Cancer Institute, Boston, MA

  • Jewish General Hospital, Montreal, QC, Canada

  • Hospital Saint Antoine, Paris, France

  • University of Manchester and The Christie NHS FT, Manchester, United Kingdom

  • Institut Gustave-Roussy, Villejuif, France

  • Academic Hospital-Uppsala University Hospital, Uppsala, Sweden

  • General Hospital of Athens, Athens, Greece

  • Nagoya City University, Nagoya, Japan

  • Cologne University, Cologne, Germany

  • Merck & Co., Inc., Kenilworth, NJ

  • University of Miami/Sylvester Cancer Center, Miami, FL

Locations

  • Italy

  • United States

  • Canada

  • United Kingdom

  • France

  • Sweden

  • Greece

  • Japan

  • Germany

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hodgkin's Lymphoma

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Adcetris

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Single Arm

  • Multicenteric

  • Cohort

Phase

  • II

Study Id's

  • NCT02453594

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved